During a satellite symposium at the ESC 2016 in Rome, organised by PACE-CME, the impact of CV disease in patients with diabetes, SGLT-2 inhibitor trial outcome data as well as the mechanism by which SGLT-2 inhibitors may affect heart function, were discussed

Since 1995, every 3-4 years a new anti-hyperglycemic category of medication has been introduced, including the SGLT-2 inhibitors in 2013

Until very recently, heart failure as a problem in diabetes was largely ignored, although it is one of the most common and most important complications in diabetes. But the EMPA-REG OUTCOME study6 put heart failure on the map; SGLT-2 inhibitors showed a remarkable reduction in heart failure hospitalisation and mortality.

Diabetes is increasing in all areas of the world and once you have diabetes, it has a tremendous impact on CV morbidity and mortality.